SCHEMBL29378299

SCHEMBL29378299

COc1ccccc1CNC(=O)c1cc(-c2ccccc2)on1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 6/20 0.65
HPGD P15428 5/20 0.65
KMT2A Q03164 5/20 0.65
MEN1 O00255 3/20 0.65
STAT3 P40763 1/20 0.65
STAT1 P42224 1/20 0.65
ALDH1A1 P00352 4/20 0.65
KDM4E B2RXH2 3/20 0.65
NPSR1 Q6W5P4 3/20 0.65
SCD5 Q86SK9 1/20 0.64
POLB P06746 1/20 0.63
HTT P42858 1/20 0.60
RAB9A P51151 3/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
NPC1 O15118 3/20 0.60
LMNA P02545 2/20 0.60
MAPK1 P28482 1/20 0.60
MAPT P10636 5/20 0.59
GAA P10253 1/20 0.58
TDP1 Q9NUW8 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3671813 0.82 ROCK2 (0.62) HSD17B10HPGDKMT2AMEN1ALDH1A1
SCHEMBL13902156 0.81 MAPT (0.88) HSD17B10HPGDKMT2AMEN1ALDH1A1
SCHEMBL12349839 0.79 RAB9A (0.76) HSD17B10HPGDKMT2AALDH1A1KDM4E
SCHEMBL21523613 0.78 SCD5 (1.00) HSD17B10HPGDKMT2AMEN1ALDH1A1
SCHEMBL17788443 0.78 HIF1A (0.68) HPGDKMT2AALDH1A1POLBRAB9A
SCHEMBL18619857 0.78 MAPT (0.67) HSD17B10HPGDKMT2AMEN1ALDH1A1
SCHEMBL5031873 0.77 POLB (0.53) HSD17B10HPGDKMT2AMEN1STAT3
SCHEMBL17652545 0.77 HIF1A (0.67) HSD17B10HPGDKMT2ASTAT3STAT1
SCHEMBL68906 0.76 HIF1A (0.70) HPGDKMT2AMEN1ALDH1A1RAB9A
SCHEMBL12349834 0.76 TP53 (0.78) HPGDKMT2AALDH1A1POLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260102351-A1 LYOPHILIZED FORMULATION OF CROFELEMER AND METHODS OF TREATMENT USING THE SAME NAPO PHARMACEUTICALS INC (US) 2026-04-16 US claimed
EP-4633622-A2 COMPOSITIONS AND METHODS FOR REGULATING PROCOAGULANT ACTIVITY AND THROMBOSIS Beth Israel Deaconess Medical Center, Inc. (US) 2025-10-22 EP claimed
EP-4593816-A2 LYOPHILIZED FORMULATION OF CROFELEMER AND METHODS OF TREATMENT USING THE SAME Napo Pharmaceuticals, Inc. (US) 2025-08-06 EP claimed
US-20240325346-A1 METHODS AND COMPOSITIONS FOR TREATING CONGENITAL DIARRHEA DISORDER NAPO PHARMACEUTICALS INC (US) 2024-10-03 US claimed
US-20240282425-A1 AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS LOW GORDON KEITH (US) 2024-08-22 US claimed
US-12064443-B2 Compositions and methods for treating diseases associated with drug washout due to fluid secretion VANESSA RESEARCH HOLDINGS, INC. (US) 2024-08-20 US claimed
EP-4408480-A1 COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE The Regents Of The University Of Michigan (US) 2024-08-07 EP claimed
EP-3634581-B1 COMPOSITIONS FOR USE IN TREATING CONGENITAL DIARRHEA DISORDER NAPO PHARMACEUTICALS INC (US) 2024-07-31 EP claimed
EP-3634455-B1 COMPOSITIONS FOR TREATING BILE ACID DIARRHEA AND SHORT BOWEL SYNDROME NAPO PHARMACEUTICALS INC (US) 2024-07-03 EP claimed
WO-2024129758-A2 COMPOSITIONS AND METHODS FOR REGULATING PROCOAGULANT ACTIVITY AND THROMBOSIS BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2024-06-20 WO claimed
EP-4294378-A1 COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH DRUG WASHOUT DUE TO FLUID SECRETION Vanessa Research, Inc. (US) 2023-12-27 EP claimed
US-20230398136-A1 COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH DRUG WASHOUT DUE TO FLUID SECRETION VANESSA RESEARCH, INC. (US) 2023-12-14 US claimed
EP-4168027-A1 METHODS AND COMPOSITIONS FOR TREATING CHEMOTHERAPY-INDUCED DIARRHEA Napo Pharmaceuticals, Inc. (US) 2023-04-26 EP claimed
WO-2023056427-A1 COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-04-06 WO claimed
US-20220362209-A1 METHODS AND COMPOSITIONS FOR TREATING CHEMOTHERAPY-INDUCED DIARRHEA NAPO PHARMACEUTICALS INC (US) 2022-11-17 US claimed
EP-4061304-A1 MULTI-CHAMBER CONTAINER Rupprecht, Holger (DE) 2022-09-28 EP claimed
WO-2022175899-A1 COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH DRUG WASHOUT DUE TO FLUID SECRETION VANESSA RESEARCH, INC. (US) 2022-08-25 WO claimed
US-11389424-B2 Methods and compositions for treating chemotherapy-induced diarrhea NAPO PHARMACEUTICALS, INC. (US) 2022-07-19 US claimed
WO-2022115481-A1 METHODS AND COMPOSITIONS FOR TREATING POST-ACUTE INFECTION GASTROINTESTINAL DISORDERS NAPO PHARMACEUTICALS, INC. (US) 2022-06-02 WO claimed
US-20220072023-A1 COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-03-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220072023-A1 COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE MYD88, STING1, TLR3 HSD17B10 4846/4885HPGD 2039/4885KMT2A 4432/4885
US-12064443-B2 Compositions and methods for treating diseases associated with drug washout due to fluid secretion SLC10A2, SI, SLC10A1 HSD17B10 1728/4885HPGD 313/4885KMT2A 4576/4885
US-20260102351-A1 LYOPHILIZED FORMULATION OF CROFELEMER AND METHODS OF TREATMENT USING THE SAME SBDS, SI, CLNS1A HSD17B10 1226/4885HPGD 2330/4885KMT2A 2207/4885
US-11389424-B2 Methods and compositions for treating chemotherapy-induced diarrhea SLC10A2, SLC26A3, SLC47A1 HSD17B10 1798/4885HPGD 1986/4885KMT2A 2701/4885
US-20230398136-A1 COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH DRUG WASHOUT DUE TO FLUID SECRETION SLC10A2, SI, SLC10A1 HSD17B10 1728/4885HPGD 313/4885KMT2A 4576/4885
US-20240325346-A1 METHODS AND COMPOSITIONS FOR TREATING CONGENITAL DIARRHEA DISORDER DSC1, PCTP, SLC26A4 HSD17B10 423/4885HPGD 667/4885KMT2A 4346/4885
US-20220362209-A1 METHODS AND COMPOSITIONS FOR TREATING CHEMOTHERAPY-INDUCED DIARRHEA SLC10A2, SLC26A3, SLC47A1 HSD17B10 1798/4885HPGD 1986/4885KMT2A 2701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.